Clozapine and cardiotoxicity - A guide for psychiatrists written by cardiologists

Area of Science:

• Cardiology
• Psychiatry
• Pharmacology

Background:

• Clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia.
• Cardiovascular side effects, including myocarditis and dilated cardiomyopathy, are rare but serious risks associated with clozapine.
• Non-specific clinical presentations complicate early detection and risk stratification.

Purpose of the Study:

• To review the proposed etiologies of clozapine-induced cardiotoxicity.
• To examine diagnostic approaches for identifying these cardiovascular complications.
• To provide guidance on management strategies for psychiatrists and physicians.

Main Methods:

• Literature review of studies on clozapine and cardiovascular adverse events.
• Analysis of proposed mechanisms, diagnostic criteria, and treatment protocols.
• Synthesis of current evidence regarding monitoring and drug reintroduction.

Main Results:

• Cardiotoxicity from clozapine presents with non-specific symptoms, challenging diagnosis.
• Accurate diagnosis is vital to avoid premature discontinuation of clozapine.
• Current recommendations involve regular monitoring of biomarkers and imaging.

Conclusions:

• Effective management of clozapine-associated cardiotoxicity requires a combination of vigilant monitoring and timely diagnosis.
• Emerging guidance on monitoring and reintroduction aims to optimize patient safety.
• Further research is needed to establish evidence-based guidelines for clozapine cardiotoxicity.